Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma
With the recent development of targeted therapies (Sorafenib, Sunitinib, Temsirolimus, Bevacizumab plus Interferon-a, Everolimus and now also Pazopanib) patients with advanced renal cell carcinoma (RCC) now have a wide range of treatment options, all of which have shown both relevant clinical activi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2011-12-01
|
| Series: | Oncology Reviews |
| Online Access: | http://www.oncologyreviews.org/index.php/or/article/view/42 |